* Abgenix Inc., of Fremont, Calif., a subsidiary of Cell Genesys, of Foster City, Calif., has acquired rights to ABX-CBL, an antibody product currently in Phase II clinical trials. ABX-CBL, previously known as CBL-1, has been tested in various acute transplant rejection indications in more than 50 patients to date. The company said it will continue Phase II trials in graft-vs.-host disease early next year after completing a confirmatory clinical study required by a manufacturing process change. ABX-CBL will be further evaluated in kidney and other organ transplant rejection indications.

No Comments